FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Curcumin Supplementation as a Preventive Strategy Against Tamoxifen-Induced Nonalcoholic Fatty Liver Disease in ER+ Breast Cancer Patients: A Triple-Blind Randomized Placebo-Controlled Trial. PMID 39948699 · J Diet Suppl · 2025 The trial is a randomized, placebo-controlled study in breast cancer patients, but the primary endpoint is the incidence of NAFLD grade change (a binary outcome), not a time-to-event endpoint. The study does not report OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios. The phase is not specified, and it does not meet the criteria for a definitive Phase III/IIIb or Phase II/III trial with a key time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Moderate Hypofractionated Post-Prostatectomy Radiotherapy (MYSTERY) Versus Conventionally Fractionated Post-Prostatectomy Radiotherapy (COPORT) for the Patients With Localized Prostate Cancer: The Protocol of a Prospective, Randomized Trial. PMID 39933701 · Cancer Control · 2025 The record is a protocol for a randomized controlled trial in oncology (prostate cancer) with time-to-event endpoints, but it is not an original formal-result report of a completed Phase III/IIIb or Phase II/III trial with a drug-containing intervention. It is a protocol document, and the intervention is radiotherapy-only, not a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acceptability and implementation potential of colorectal cancer screening and health literacy training: A qualitative study among general practitioners in deprived areas. PMID 39932910 · PLoS One · 2025 The record describes a qualitative study nested within a cluster-randomized controlled trial, focusing on acceptability and implementation of training for general practitioners. It does not report results of a randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (OS, PFS, etc.) from a Phase III or definitive Phase II/III study. The primary endpoint is qualitative acceptability, not an efficacy outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial. PMID 39917581 · JCO Oncol Adv · 2025 The record describes a randomized trial with a drug intervention and time-to-event efficacy endpoint in oncology, but the trial phase is not explicitly stated in the provided metadata or abstract. The deterministic review notes phase evidence is unclear. Without explicit confirmation of Phase III/IIIb or Phase II/III status, the record cannot be considered eligible. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Recombinant Human Thrombopoietin (rhTPO) on Coagulation Function and Inflammatory Factors in the Treatment of Patients with Sepsis-Related Thrombocytopenia. PMID 39901742 · Clin Appl Thromb Hemost · 2025 The study is a randomized controlled trial of a drug (rhTPO) in humans, but it is not an oncology study. It investigates sepsis-associated thrombocytopenia, which is not a human malignant neoplasm. Furthermore, while mortality is reported, the study does not explicitly present a primary or key secondary time-to-event efficacy endpoint with Kaplan-Meier or hazard ratio analysis as required by the cohort definition. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Commensurate Prior Model With Random Effects for Survival and Competing Risk Outcomes to Accommodate Historical Controls. PMID 39846144 · Pharm Stat · 2025 The record describes a statistical methodology paper that applies a model to a phase III clinical trial, but it is not the original formal-result report of the trial itself. The application is to a non-drug intervention (bone marrow/cord blood transplant). No time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) is explicitly reported in the abstract. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of functional re-education and environmental adaptation in cancer patients with respiratory pathology: Study protocol. PMID 39787149 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluating the effects of time-restricted eating on overweight and obese women with polycystic ovary syndrome: A randomized controlled trial study protocol. PMID 39787136 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of different educational interventions on cervical cancer knowledge and human papillomavirus vaccination uptake among young women in Japan: Preliminary results of a cluster randomized controlled trial. PMID 39774513 · PLoS One · 2025 The record describes a randomized trial in an oncology context (cervical cancer/HPV vaccination) but lacks a drug-containing intervention (vaccination is preventive, not a therapeutic drug for cancer) and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) for a cancer treatment. It is not a Phase III/IIIb or Phase II/III therapeutic trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. PMID 39774508 · PLoS One · 2025 Eligibility requires a drug-containing intervention and a specified definitive Phase III/IIIb or Phase II/III trial. The record describes a randomized trial of a biomarker test for screening, not a drug intervention. The trial phase is unclear from the provided metadata. Therefore, the record is excluded based on the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma. PMID 39612268 · Crit Rev Biomed Eng · 2025 The study is a randomized trial in oncology patients with a drug intervention (Tuhuanglian liquid wet compress), but it does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios. The primary outcome is the severity (RTOG grading) and time to develop grade 3 dermatitis, which is a toxicity/safety endpoint, not an efficacy endpoint. The trial phase is not specified in the record. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prospective Evaluation of Supplemental External Beam Radiation Therapy With Palladium-103 Prostate Brachytherapy: Long-Term Results of the 44/20/0 Trials. PMID 39447863 · Pract Radiat Oncol · 2025 The trial phase is not explicitly established as Phase III/IIIb or Phase II/III from the provided metadata, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Application Value of Iodine-131 Combined with Levothyroxine Sodium in Patients with Differentiated Thyroid Cancer after Surgery. PMID 39307136 · Oncology · 2025 The study is a randomized, oncology trial with a drug intervention and primary results. However, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, recurrence-free survival with Kaplan-Meier/HR). The primary outcomes are treatment effectiveness rate, thyroglobulin levels, and recurrence rate at 1 year, but the recurrence analysis is not presented as a time-to-event (e.g., Kaplan-Meier curve or hazard ratio). Additionally, the phase is not explicitly stated as Phase III/IIIb or II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). PMID 39233006 · Pract Radiat Oncol · 2025 Record is excluded due to absence of a drug intervention and absence of a primary/key secondary time-to-event efficacy endpoint. The abstract reports on centralized quality assurance and treatment plan compliance for stereotactic body radiation therapy in a randomized trial, but does not present survival or time-to-event efficacy data. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of SBRT plus immunotherapy on immune status and survival quality of NSCLC patients: A study of combined radiotherapy and immunotherapy. PMID 39177632 · Technol Health Care · 2025 The study is an original randomized trial in human oncology (NSCLC) with a drug-containing intervention (immunotherapy). However, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR data; outcomes are efficacy rates, tumor markers, immune cells, and quality-of-life scores (KPS). Furthermore, the phase is not specified as Phase III/IIIb or Phase II/III, and cannot be reliably inferred from the title, abstract, or metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An exploration into the relationship between insomnia and repetitive negative thinking among cancer survivors. PMID 38831557 · J Psychosoc Oncol · 2025 This is a secondary analysis of a pilot randomized trial of non-drug CBT-I for insomnia in cancer survivors. It is not a Phase III or definitive randomized trial, does not involve a drug intervention, and reports no time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses. PMID 39343511 · J Immunother Cancer · 2024-Sep-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. PMID 39321362 · N Engl J Med · 2024-Sep-26 Eligibility fails on oncology, randomization, and primary endpoint criteria. The study is a Phase III gene therapy trial for hemophilia B, not cancer. It is single-arm, not randomized. Its primary endpoint is a count-based rate (annualized bleeding rate), not a time-to-event or Kaplan-Meier outcome. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Impacts of participation in surgical clinical trial on safety and survival outcomes in patients with right-sided colon cancer]. PMID 39313432 · Zhonghua Wei Chang Wai Ke Za Zhi · 2024-Sep-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. PMID 39317942 · Breast Cancer Res · 2024-Sep-24 The record describes a secondary, biomarker-focused analysis pooling data from three separate randomized trials (GeparQuattro, GeparQuinto, GeparSixto). While the underlying trials are likely Phase III, the publication itself is not the primary efficacy report of a single trial. The study's primary goal is to correlate on-treatment biopsies with pathologic complete response and disease-free survival, not to report the definitive trial outcome. Therefore, it does not meet the inclusion criteria for an original formal-result report of a single Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A phase 2 study of a longitudinal multidimensional rehabilitation program for allogeneic blood and marrow transplantation patients. PMID 38985303 · Blood Adv · 2024-Sep-24 The trial is a phase 2 randomized controlled trial evaluating a rehabilitation program, not a drug intervention. It lacks a phase 3 designation and a time-to-event efficacy endpoint, which are required for eligibility. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies. PMID 39313302 · RMD Open · 2024-Sep-23 The report is a Phase III randomized controlled trial of a drug (bimekizumab) for psoriatic arthritis, which is an autoimmune/inflammatory condition, not a malignant neoplasm (oncology). While it is a human, randomized, phase III trial with a drug intervention and presents primary results, it fails the core 'oncology' criterion. Furthermore, the endpoints are patient-reported outcomes (pain, fatigue, function, quality of life), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. PMID 39313288 · BMJ Open · 2024-Sep-23 The record describes a qualitative study embedded in the SCOPE2 trial, not the primary or key secondary efficacy results of the randomized trial. The study explores patient experiences and quality of life, not time-to-event endpoints like OS or PFS. While the underlying SCOPE2 trial is randomized and oncology-focused, this specific publication does not report the trial's efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. PMID 39306468 · Lancet · 2024-Sep-21 The record describes a definitive randomized controlled trial (TransMet) with a primary time-to-event efficacy endpoint (overall survival, reported as 5-year percentages and HR). The intervention includes chemotherapy (drug) in both arms. While the specific phase is not explicitly stated in the provided metadata, the trial's design (multicentre, definitive, RCT) and its registration as a prospective controlled trial meet the criteria for a definitive oncology trial. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Radiograph accelerated detection and identification of cancer in the lung (RADICAL): a mixed methods study to assess the clinical effectiveness and acceptability of Qure.ai artificial intelligence software to prioritise chest X-ray (CXR) interpretation. PMID 39306349 · BMJ Open · 2024-Sep-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol. PMID 39304797 · BMC Cancer · 2024-Sep-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer. PMID 39164816 · Chin Med J (Engl) · 2024-Sep-20 The record is a secondary analysis (genomic correlates) aggregating data from multiple phase 3 trials. It is not the original formal result report of a single randomized trial. The abstract focuses on identifying predictive biomarkers and does not explicitly report a time-to-event primary efficacy endpoint (e.g., OS/PFS with KM curves or HR) as the main result. Therefore, it does not meet the criteria for a primary efficacy report from a definitive randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. PMID 38760158 · BMJ Evid Based Med · 2024-Sep-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of long-term low-dose aspirin in the prevention of gastric cancer after Helicobacter pylori eradication: study design and rationale of Ardabil gastric cancer randomized placebo-controlled prevention trial (AGCPT). PMID 39300505 · Trials · 2024-Sep-19 This is a study design and rationale paper for a randomized trial, not a report of trial results. It describes a protocol without providing any efficacy data, phase is not explicitly stated, and the publication type is 'Clinical Trial Protocol'. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. PMID 39300447 · J Hematol Oncol · 2024-Sep-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol. PMID 39300376 · BMC Cancer · 2024-Sep-19 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial. PMID 38871464 · Thorax · 2024-Sep-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized dose-response trial of n-3 fatty acids in hormone receptor negative breast cancer survivors- impact on breast adipose oxylipin and DNA methylation patterns. PMID 39371146 · medRxiv · 2024-Sep-16 The study is a randomized trial in breast cancer survivors but evaluates dietary n-3 fatty acid supplementation (not a drug) and reports biomarker/epigenetic outcomes, not time-to-event efficacy endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative. PMID 38736319 · Cancer · 2024-Sep-15 The record is a secondary analysis of a large randomized dietary intervention trial. It does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III randomized trial evaluating a specific drug intervention for efficacy, and the primary outcomes are epidemiological associations (incidence, mortality risk) rather than a formal time-to-event efficacy endpoint (e.g., OS, PFS) from a drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Modified Banxiaxiexin decoction benefitted chemotherapy in treating gastric cancer by regulating multiple targets and pathways. PMID 38697407 · J Ethnopharmacol · 2024-Sep-15 The record describes a randomized, controlled trial in human gastric cancer patients with drug intervention and OS/PFS endpoints, consistent with a definitive trial. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata or abstract, making it impossible to definitively confirm phase eligibility. The 'deterministic_review' also flags phase evidence as unclear. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium. PMID 38676430 · Int J Cancer · 2024-Sep-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers-Simple Tools Matter. PMID 39330032 · Curr Oncol · 2024-Sep-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Research on the soothing Liver - Qi stagnation method in the treatment of postoperative papillary thyroid carcinoma patients' concomitant depression: A randomized controlled clinical trial. PMID 39287310 · Medicine (Baltimore) · 2024-Sep-13 The study is a randomized controlled trial evaluating a Chinese herbal medicine for depression in postoperative thyroid cancer patients. It is oncology-related and human, but it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for the cancer. The primary endpoint is depression scores (HAMD), which is not a cancer efficacy endpoint. Phase is not specified as definitive (Phase III/IIIb or Phase II/III). Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer. PMID 39272058 · BMC Cancer · 2024-Sep-13 The study is an oncology Phase III randomized trial with a drug intervention and reports original results. However, it fails the key requirement of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR for efficacy). The primary endpoint (duration of neutropenia) is a safety/toxicity measure, not a survival or progression endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. PMID 39058429 · Clin Cancer Res · 2024-Sep-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON). PMID 39028916 · Clin Cancer Res · 2024-Sep-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial. PMID 38995291 · Clin Cancer Res · 2024-Sep-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC. PMID 38901425 · Med · 2024-Sep-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial. PMID 39267010 · BMC Cancer · 2024-Sep-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype. PMID 39261919 · Clin Epigenetics · 2024-Sep-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. PMID 39261451 · Blood Cancer J · 2024-Sep-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Needs, preferences, and patient participation for a randomized controlled trial on postneoadjuvant complete tumor response: A qualitative study of patients with esophageal cancer. PMID 39256205 · Support Care Cancer · 2024-Sep-11 The record is a qualitative study on patient participation in a potential RCT, not a formal report of a completed randomized trial with a drug intervention and a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease. PMID 39028926 · J Clin Oncol · 2024-Sep-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315). PMID 38843469 · J Clin Oncol · 2024-Sep-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunological effects of post-operative epidural analgesia versus oral opioids in VATS. PMID 39323258 · Dan Med J · 2024-Sep-09 The study is a randomized, controlled, double-blinded trial in humans with lung neoplasms (oncology), but it lacks a drug-containing intervention (compares epidural analgesia vs. oral morphine, which are analgesic techniques, not novel oncology drugs) and does not report a primary time-to-event efficacy endpoint (OS, PFS, etc.); the two-year survival follow-up is mentioned but not presented as a formal Kaplan-Meier curve or hazard ratio for efficacy. Phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |